NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Xenetic Biosciences, Inc. (XBIO) Stock Analysis

Xenetic Biosciences, Inc. (XBIO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

XBIO

$4.67

+$0.04 (+0.86%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare XBIO with… →

XBIO Key Statistics

As of Sep 4, 2026
Trading
Open
$4.73
Previous Close
$4.63
Day's Range
4.41–4.90
52-Week Range
1.90–13.93
Volume
79.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.24
Valuation
Market Cap
$10.94M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.36
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.15
Financials (FY)
Revenue (FY)
$2.98M+19.04%
Net Income (FY)
−$2.68M
Profit marginThe share of revenue left as profit after all costs and taxes.
−75.91%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.34M
1-Year Return
+51.82%
Dividend and dates
Avg Volume
39.07K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

XBIO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+115.21%
2025−45.61%
2024+15.65%
2023+21.05%
2022−77.91%
2021−36.76%
2020+41.67%
2019−92.68%
2018−14.54%
2017−55.37%
2016 (partial year)−0.46%

As of September 4, 2026.

XBIO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.98M−$2.68M−90.1%
2024$2.50M−$3.96M−158.4%
2023$2.54M−$4.13M−162.8%
2022$1.71M−$6.55M−383.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.98M—−$2.83M−$2.68M−90.1%
2024$2.50M—−$4.20M−$3.96M−158.4%
2023$2.54M—−$4.52M−$4.13M−162.8%
2022$1.71M—−$6.72M−$6.55M−383.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

XBIO Valuation vs Biotechnology Median

Median of 656 stocks
MetricXBIOBiotechnology medianvs median
P/S ratio3.3615.260.2x the median
Profit margin−75.91%0.00%75.9 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Xenetic Biosciences, Inc. (XBIO) is capitalised at $10.94M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 2.

Over the past 52 weeks the price has ranged from $1.90 to $13.93. XBIO last closed at $4.67 on September 4, 2026. That is +$0.04 (+0.86%) against the previous close. The latest close sits 145.79% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $2.98M. That is +19.04% against the prior fiscal year, when revenue was $2.50M. The same year closed with a net loss of $2.68M. Profit margin runs at −75.91%. That is 75.9 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −1.15.

Across the 4 fiscal years on file, revenue moves from $1.71M in 2022 to $2.98M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 3.36 times revenue. On price-to-sales that is 0.2 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 2.24. Daily returns over the trailing 10 years annualize to a volatility of 133.93%. The trailing one-year price return is +51.82%. Across 10 years the annualized return works out at −38.53%.

Growth & Income

The record shows no dividend for XBIO.

So far in 2026 the price is +115.21%. The strongest complete calendar year on file is 2020 at +41.67%; the weakest is 2019 at −92.68%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

Xenetic Biosciences, Inc. (XBIO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Xenetic Biosciences, Inc. XBIO $10.94M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Xenetic Biosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various research, development, license and supply agreements with Serum Institute of India, PJSC Pharmsynthez, and SynBio, LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Visit website →